Achillion Pharmaceuticals has announced sustained viral response ( SVR4 ) results of 85 to 100% from an ongoing multi-dose Phase 2 trial evaluating 12 weeks of dosing with Sovaprevir ( formerly ACH-1625 ), a once-daily protease inhibitor, in combination with Pegylated Interferon plus Ribavirin followed by an additional 12 weeks of PegInterferon plus Ribavirin.

In June 2011, Achillion initiated a randomized phase 2 trial evaluating three doses ( 200 mg, 400 mg, or 800 mg ) of Sovaprevir given once daily in combination with Pegylated Interferon plus Ribavirin for 12 weeks followed by an additional 12 or 36 weeks of PegInterferon plus Ribavirin, for the treatment of genotype 1 HCV.

Of the 58 patients enrolled in this study, the majority had HCV genotype 1a ( n=35 [ 60%] ), with remaining patients having HCV genotype 1b ( n=20 ) or genotype 1 ( n=3 ).
Approximately 71% of the patients were IL28B genotype CT/TT, the more difficult to treat mutation, 64% were male and 17% were African American.

The complete early virologic responses ( cEVR ) across the 200 mg, 400 mg, and 800 mg Sovaprevir dose groups were 100%, 94% and 100%, respectively.

Achillion has reported SVR4 rates of 90%; 85%; and 100% in the 200 mg, 400 mg, and 800 mg dose groups, respectively, after 24 weeks of therapy consisting of 12 weeks of Sovaprevir and PegInterferon plus Ribavirin followed by additional 12 weeks of PegInterferon plus Ribavirin. In all, 39 patients were assigned to receive an additional 12 weeks of PegInterferon plus Ribavirin therapy with the remaining 14 patients assigned to receive an additional 36 weeks of PegInterferon plus Ribavirin. ( Xagena )

Source: Achillion Pharmaceuticals, 2012

XagenaMedicine_2012